Transparency comments sought
This article was originally published in The Tan Sheet
Executive Summary
FDA seeks comments on how to improve the agency's transparency to regulated firms, based on input received during Transparency Task Force meetings in January with food, drug and medical device industry representatives. Transcripts from those sessions are accessible at 1www.regulations.gov and on the task force's Web site, 2www.fda.gov/Transparency, according to a March 12 release. FDA is particularly interested in comments on how to make improvements in training and education for regulated industry about FDA's regulatory process in general or about specific new requirements; the guidance development process; maintaining open channels of communication with industry routinely and during crises; providing useful and timely answers to industry questions about specific regulatory issues; and communicating with sponsors during review of applications. Comments are due by April 12
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.